More than 7 million of those deaths are the result of direct tobacco use while around 1.2 million are the result of non-smokers being exposed to second-hand smoke. Moreover, the usage of tobacco is more in developing and underdeveloped countries. Tobacco and its usage through consumption and smoking are harmful, as it kills half of its users globally, as stated by the World Health Organization.
In addition, the high reluctance of individuals for accessing treatment modalities and poor treatment compliance in some countries hinder the growth of the market studied.The research includes historic data from 2015 to 2020 and forecasts until 2026 which makes the report an invaluable resource for industry executives, marketing, sales, and product managers, consultants, analysts, and stakeholders looking for key industry data in readily accessible documents with clearly presented tables and graphs.
The data from the WHO also states that tobacco kills more than 8 million people each year.
Evercore ISI analyst Josh Schimmer resumed coverage of AbbVie stock with an Outperform rating and $111 price target.
AbbVie’s cash cow is Humira, which accounts for about 60% of its total revenue.
AbbViehas been able to outpace the S&P 500 since its spinoff from Abbott Labs in early 2013. AbbVie is placing a lot of faith in Skyrizi and Rinvoq, and estimates that the two will earn revenues >$10bn, and possibly more than $20bn, by 2025. Jul. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.Irfan Tamboli (Head of Sales) – Market Insights ReportsPhone: + 1704 266 3234 | +91-750-707-8687the discontinuation of behavioral therapies often leads to a relapse of addiction, which is a crucial factor hindering the growth of the market. It helps to gain stability in the businesses as well as to make the rapid developments to achieve a notable remark in the Global market space.The report titled "Substance Abuse Treatment Market" has recently added by MarketInsightsReports to get a stronger and effective business outlook. Despite the understanding of the general population that E-Cigarette is less harmful, studies have indicated that the E-cigarette consumption leads to several serious health issues associated with tobacco. Although AbbVie's near-term valuation and share price growth prospects are hard to determine owing to the Allergan deal, I believe the long-term outlook is favorable.The company is well-known for its generous dividend which yields 4.8% at time of writing - 2x more than LLY.In May, AbbVie completed the acquisition of Allergan, whose Botox and Juvederm brands drove ~$5bn of the company's $16bn of revenues in FY19.Big Pharma is an underperforming sector of the stock market, but AbbVie's 1yr and 5yr share price gains are second only to Eli Lilly.Revenues from Humira may exceed 2019's $19.1bn in FY20 as sales growth in US outpaces declines in Europe owing to biosimilar competition. Worldwide Dry Eye Disease Industry to 2025 - Featuring AbbVie, Alcon & VISUfarma Among Others - ResearchAndMarkets.com DUBLIN--(BUSINESS WIRE)--The "Dry Eye Disease Market - Growth, Trends, and Forecasts (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering. AbbVie was founded as a spin-off of Abbott Laboratories in 2013 and is one of the six US “big pharma” companies. Substance Abuse Treatment Market – Growth, Trends, And Forecasts (2020 – 2025) The report titled "Substance Abuse Treatment Market" has recently added by MarketInsightsReports to get a stronger and effective business outlook. Segments, Competitive Landscape and Forecast to 2025. Worldwide Dry Eye Disease Industry to 2025 - Featuring AbbVie, Alcon & VISUfarma Among Others - ResearchAndMarkets.com DUBLIN--(BUSINESS WIRE)--The "Dry Eye Disease Market - Growth, Trends, and Forecasts (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.